CORT
Corcept Therapeutics IncorporatedHealthcare · $12.5B market cap
Verdict
Share price
$116.23
close of Oct 3, 2026
Fair value
$35.20
Sticker Price
Payback Price
$14.08
buy price
CORT is Overpriced: at $116.23 it trades 230% above its fair value of $35.20. Its buy price (Payback Price) is $14.08, 88% below today's price. Business quality is strong: 4 of 5 key numbers clear the 10% bar.
How we valued it
Earnings Power. Our 10-year earnings projection came out at less than a fifth of the share price, too far from reality to publish. So we use a simpler measure: today's normal earnings at the price-to-earnings ratio it has typically traded at.
Business quality
4 of 5 clear the 10% bar. What are the Big Five?
Follow CORT
Get notified when it reaches its buy price of $14.08. Free.
Create a free accountInsider activity
Since Sep 1, 2026: no open-market purchases, 10 sales worth $9.3M and 19 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-02
Sold
$141K
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-02
Sold
$644K
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-02
Sold
$183K
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-02
Sold
$109K
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-02
Sold
$171K
Other filings
Lyon Joseph Douglas
See Remarks · 2026-09-02
Tax withholding
$8K
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-02
Option exercise
$1.3M
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-02
Tax withholding
$12K
Robb Gary Charles
Chief Business Officer · 2026-09-02
Tax withholding
$10K
Mokari Atabak
Chief Financial Officer · 2026-09-02
Tax withholding
$12K
Show all 19 other filingsShow fewer
Maduck Sean
See Remarks · 2026-09-02
Tax withholding
$13K
Lyon Joseph Douglas
See Remarks · 2026-09-01
Award
130 shares
Lyon Joseph Douglas
See Remarks · 2026-09-01
Award
$15K
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-01
Award
138 shares
Vieira Roberto Wandenkolk
President, Oncology · 2026-09-01
Award
$16K
Robb Gary Charles
Chief Business Officer · 2026-09-01
Award
164 shares
Robb Gary Charles
Chief Business Officer · 2026-09-01
Award
$19K
Mokari Atabak
Chief Financial Officer · 2026-09-01
Award
138 shares
Mokari Atabak
Chief Financial Officer · 2026-09-01
Award
$16K
Maduck Sean
See Remarks · 2026-09-01
Award
150 shares
Maduck Sean
See Remarks · 2026-09-01
Award
$17K
Maduck Sean
See Remarks · 2026-09-01
Option exercise
$207K
Guyer William
Chief Development Officer · 2026-09-01
Award
164 shares
Guyer William
Chief Development Officer · 2026-09-01
Award
$19K
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for…
Medical - Pharmaceuticals
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works